| Previous Close | 7.36 |
| Volume | 322,751 |
| Price / Earnings (Forward) | 15.30 |
| Price / Sales | 2.34 |
| Price / Book | 1.69 |
| 52 Weeks Range | |
| TTM Dividend Yield | 5.79% |
| Profit Margin | 9.60% |
| Operating Margin (TTM) | 17.71% |
| Diluted EPS (TTM) | 0.280 |
| Quarterly Revenue Growth (YOY) | 16.60% |
| Quarterly Earnings Growth (YOY) | 67.60% |
| Total Debt/Equity (MRQ) | 4.41% |
| Current Ratio (MRQ) | 3.30 |
| Operating Cash Flow (TTM) | 46.06 M |
| Levered Free Cash Flow (TTM) | 36.83 M |
| Return on Assets (TTM) | 4.14% |
| Return on Equity (TTM) | 6.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Kamada Ltd. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 4.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | 5.0 |
| Financial Health | 2.9 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.78 |
Select this tab to load the latest available analysis.
|
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 7.22% |
| % Held by Institutions | 48.70% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Phoenix Financial Ltd. | 30 Jun 2026 | 1,654,952 |
| Huntleigh Advisors, Inc. | 30 Sep 2026 | 168,072 |
| Acadian Asset Management Llc | 30 Jun 2026 | 154,375 |
| Renaissance Group Llc | 30 Jun 2026 | 124,896 |
| Two Sigma Advisers, Lp | 31 Dec 2025 | 99,700 |
| Marshall Wace, Llp | 30 Jun 2026 | 75,182 |
| Man Group Plc | 30 Jun 2026 | 61,889 |
| Envestnet Asset Management Inc | 30 Jun 2026 | 54,669 |
No data within this time range.
| TTM Dividend Yield | 5.79% |
| 1Y Average Dividend Yield | 2.83% |
| Expected Next Dividend Payment | Apr 2027 |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 27 Aug 2026 | 17 Aug 2026 | 17 Sep 2026 | 0.17 Cash |
| 23 Mar 2026 | 11 Mar 2026 | 07 Apr 2026 | 0.25 Cash |
| 17 Mar 2025 | 05 Mar 2025 | 07 Apr 2025 | 0.2 Cash |
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 0.420 | 2 | 5.79 |
| 2025 | 0.200 | 1 | 2.83 |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |